[Recombinant XXXX for the management of intracardiac thrombi in newborns].

@entity1 @entity295 @entity932 @entity1456 @entity6950 @entity887 @entity299 @entity715
INTRODUCTION: The incidence of @entity299 in newborns has increased with the use of central venous catheters. Thrombolysis with recombinant @entity1456 (rTPA) has been used as an alternative to @entity6950 in life threatening @entity887 . The aim of this study is to describe the response and complications related to the use of rTPA in the management of life- threatening @entity299 in newborns. @entity1 AND METHOD: The medical records of 8 newborn were reviewed in a retrospective study, of whom 7 were preterm with @entity299 , and rTPA was used in all of them. RESULTS: The @entity1 included 4 males with a mean weight of 1580 gr. The principal pathology was @entity295 (7/8), all of them used venous central catheter. The superior vena cava was the most frequent location, with a mean time of installation before the diagnosis of 12 days. RN 7/8 thrombi were located in the right atrium with a size between 7 to 20 mm. Three @entity1 received low molecular weight heparin prior to using rTPA. They received between 1 to 5 cycles with rTPA. In 4 @entity1 complete resolution of the @entity715 was achieved in a mean of 3.5 days. Four @entity1 had @entity932 grade I, without sequelae at follow-up. There were no deaths or @entity887 . CONCLUSION: This study is the first series of @entity1 treated with rTPA in Chile, and where its use has quickly achieved complete resolution of the @entity715 in 50% of cases, and partially in the others, thus reducing the secondary life-threatening risk of this disease.
